focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,108.00
Ask: 12,112.00
Change: -62.00 (-0.51%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Lower open ahead of BoE, ECB; Currys swings to loss

Thu, 15th Dec 2022 07:49

(Alliance News) - Stock prices in London are set to open lower on Thursday, after the US Federal Reserve raised interest rates as expected and ahead of three more central bank decisions.

The Fed hiked rates by 50 basis points, as widely expected, but also forecast that interest rates will peak at a higher level than previously expected.

The Federal Open Market Committee lifted the target range for the federal funds rate to 4.25% to 4.50% - the highest since 2007 - from the previous range of 3.75% to 4.00%.

"The committee anticipates that ongoing increases in the target range will be appropriate in order to attain a stance of monetary policy that is sufficiently restrictive to return inflation to 2% over time," the Fed explained.

The Swiss National Bank will kick off Thursday's busy day for central bank decisions at 0830 GMT, before the Bank of England announces its interest rate decision at midday, followed shortly afterward by the European Central Bank.

China's retail sales plunged last month, official data showed, as Covid restrictions and a property market crisis hammered the world's second-largest economy.

The figures highlight the work ahead for the government as it moves away from almost three years of strict containment measures that have whittled growth and sent shudders through supply chains.

November retail sales sank 5.9% year-on-year, marking the second successive contraction, according to data released by the National Bureau of Statistics.

In early company news in London, electronics retailer Currys fell into a half-year loss, due to an impairment. Outsourcer Serco raised its 2022 guidance, and oil field services provider Hunting raised 2023 guidance.

Here is what you need to know ahead of the London market open:

----------

MARKETS

----------

FTSE 100: called down 27.63 points, or 0.4%, at 7,468.30

----------

Hang Seng: down 1.5% at 19,373.22

Nikkei 225: closed down 0.4% at 28,051.70

S&P/ASX 200: closed down 0.6% at 7,204.80

----------

DJIA: closed down 0.4%, at 33,966.35

S&P 500: closed down 0.6% at 3,995.32

Nasdaq Composite: closed down 0.8% at 11,170.89

----------

EUR: lower at USD1.0652 (USD1.0660)

GBP: lower at USD1.2387 (USD1.2410)

USD: higher at JPY135.77 (JPY134.82)

Gold: lower at USD1,792.36 per ounce (USD1,810.74)

(Brent): lower at USD82.00 a barrel (USD82.51)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

14:15 CET EU ECB interest rate announcement

11:00 GMT Ireland goods exports and imports

12:00 GMT UK BoE MPC meeting minutes

12:00 GMT UK interest rate decision

08:30 EST US advance monthly sales for retail and food services

08:30 EST US Philadelphia Fed business outlook survey

08:30 EST US unemployment insurance claims report

08:30 EST US weekly export sales

09:15 EST US industrial production

16:00 EST US treasury international capital data

16:30 EST US Foreign Central Bank holdings

16:30 EST US federal discount window borrowings

----------

Tens of thousands of nurses are going on strike for the first time across England, Wales and Northern Ireland. Picket lines are being set up at dozens of hospitals in a dispute over pay, with the Welsh government saying services will be "significantly impacted". Thousands of NHS appointments and operations have been cancelled because of the strike, with the health service running a bank holiday-style service in many areas. The Royal College of Nursing has said it will still staff chemotherapy, emergency cancer services, dialysis, critical care units, neonatal and paediatric intensive care. Some areas of mental health and learning disability and autism services are also exempt, while trusts have been told they can request staffing for specific clinical needs. When it comes to adult A&E and urgent care, nurses will work Christmas Day-style rotas.

----------

BROKER RATING CHANGES

----------

Deutsche Bank raises AstraZeneca price target to 13,000 (12,000) pence - 'buy'

----------

Goldman Sachs raises Big Yellow to 'buy' ('neutral') - price target 1,250 (1,130) pence

----------

Barclays raises Victorian Plumbing to 'overweight' ('equal-weight') - price target 100 (75) pence

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm AstraZeneca, alongside US peer Merck & Co, announced that the US Food & Drug Administration will extend the Prescription Drug User Fee Act date by three months to allow further time for a full review of the supplementary new drug application of Lynparza in combination with abiraterone and prednisone or prednisolone. The review is for Lynparza in combination for the treatment of metastatic castration-resistant prostate cancer.

----------

SSE's SSEN Transmission arm welcomed UK Ofgem's approval of transmission investments needed to meet the UK government's 50 gigawatt offshore wind target by 2030. The electricity provider said the decision by the regulator confirms that all SSEN transmission projects will be taken forward as part of the Accelerated Strategic Transmission Investment framework. As a result, two 2 gigawatt subsea high-voltage direct current links will be taken forward as joint ventures with National Grid Electricity Transmission, amongst other projects. Ofgem also confirmed these will be exempt from proposals to introduce competitive ownership of onshore electricity networks. National Grid said it welcomed the clarity that the Ofgem decision gives to NGET. Ofgem said the ASTI framework streamlines the onshore transmission regulatory approval process in the UK.

----------

COMPANIES - FTSE 250

----------

Currys swung sharply to a loss in the six months ended October 29, as revenue declined. The electricals retailer posted a pretax loss of GBP548 million, swinging from a profit of GBP48 million in the previous year. Revenue fell to GBP4.47 billion from GBP4.79 million. More significantly, Currys booked an impairment of goodwill of GBP511 million in the half-year, compared to no such impairment a year before. It said this arose at the time of the Dixons Carphone merger in 2014. Currys also noted lower international profits and margin for the swing to a loss. The company now expects full-year pretax profit to be between GBP100 million and GBP125 million. In the first six weeks of the second half, trading has been in-line with the first half.

----------

Outsourcer Serco said it expects its 2022 results to be "slightly" ahead of previous guidance and added its 2023 results are due to be in-line with expectations. Revenue for 2022 is expected at GBP4.5 billion, Serco said, slightly above 2021 despite a reduction in Covid-related revenue. Underlying trading profit is expected at GBP235 million, representing a GBP5 million increase on the firm's previous guidance. For 2023, underlying trading profit is expected to be similar to 2022 at GBP235 million. Chief Executive Rupert Soames said: "2022 will turn out much better than we expected at the start of the year as strong growth across the business largely replaced Covid contracts. Revenue is expected to be 8% higher and underlying trading profit around 20% better than we anticipated when we first gave guidance in December 2021." Soames steps down at the end of the year, replaced by Mark Irwin, currently CEO of Serco's UK & Europe business.

----------

OTHER COMPANIES

----------

Hunting said that its 2022 trading and financial outturn remains in-line with market expectations, with earnings before interest, tax, depreciation and amortisation predicted at USD50 million. The oil and gas industry services provider added that its sales order book continues to improve, with the order book now approaching USD500 million. For 2023, Hunting raised guidance for Ebitda to between USD85 million and USD90 million, up from USD80 million previously. Chief Executive Jim Johnson said: "2022 has been a year of rebuilding for the industry with 2023 now likely to be a strong year of growth for the group. All of our operating segments are reporting good levels of enquiries, and with our order book now approaching USD500 million, our earnings visibility for the year ahead is robust, despite recessionary fears."

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.